Gastric Cancer News

Rare Cancer: Decision to remove healthy stomach daunts family ... - The Sydney Morning Herald



Rare Cancer: Decision to remove healthy stomach daunts family ... 
The Sydney Morning Herald
Jemma Caprioli is preparing herself for radical surgery to remove what could be a perfectly healthy stomach.

and more » 


BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer - Nasdaq



BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer 
Nasdaq
BioLineRx Ltd.BLRX announced that its partner Genentech, a member of Roche Holding AG RHHBY , has initiated a phase Ib/II study to evaluate its lead pipeline candidate, BL-8040, in combination with Roche's Tecentriq (atezolizumab) for treating patients ...

and more » 


Activating Helicobacter effector delivery - Nature.com



Activating Helicobacter effector delivery 
Nature.com
Helicobacter pylori is a human bacterial pathogen that colonizes the gastric mucosa and, in some infected individuals, can cause various diseases ranging from gastritis to gastric cancer. H. pylori uses a type IV secretion system (T4SS) to inject ...

 


Keytruda Approved for Some Patients With Gastric Cancer - Curetoday.com



Curetoday.com
 
Keytruda Approved for Some Patients With Gastric Cancer 
Curetoday.com
Keytruda (pembrolizumab) was granted FDA approval for the treatment of patients with recurrent or advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received two or more lines of chemotherapy and are PD-L1-positive.
Merck's Keytruda resumes regulatory hot streak with stomach cancer approval FiercePharma
Merck's Keytruda Gets FDA Nod for Advanced Gastric Cancer Zacks.com
Keytruda Gains Additional Use in Advanced Gastric Cancers Monthly Prescribing Reference
Managed Care magazine  -Technology Networks 
all 8 news articles » 


Alterations in gene regulation make gastric cancer cells less visible to the immune system - Medical Xpress



Alterations in gene regulation make gastric cancer cells less visible to the immune system 
Medical Xpress
Gastric cancer cells are helped to evade the immune system by alterations in gene regulation, according to new work by A*STAR researchers. This mechanism might apply to a wide range of cancers, and could be exploited to improve cancer treatments.

 


Expert Discusses Continued Growth of Immunotherapy in Gastric/GEJ Cancer - OncLive



OncLive
 
Expert Discusses Continued Growth of Immunotherapy in Gastric/GEJ Cancer 
OncLive
?Immunotherapy, in terms of biomarker-unselected populations, is probably the most promising [treatment] that we have identified in gastric/GEJ cancer,? said Harry H. Yoon, MD, co-chair, Esophageal/Gastric Cancer Disease Group, at Mayo Clinic.

 


FDA Approvals in HCC and Gastric Cancer, ODAC Panel Splits on Adjuvant RCC Treatment, and More - OncLive



OncLive
 
FDA Approvals in HCC and Gastric Cancer, ODAC Panel Splits on Adjuvant RCC Treatment, and More 
OncLive
FDA approvals in liver cancer and gastric cancer, an FDA panel splits on a kidney cancer treatment, and European approvals for lung cancer, bladder cancer, and Merkel cell carcinoma. Welcome to OncLive News Network! I'm Gina Columbus. The FDA has ...

and more » 


Merck & Co.'s Keytruda Gets FDA Approval for Gastric Cancer - Pharmaceutical Technology Magazine



Immuno-Oncology News
 
Merck & Co.'s Keytruda Gets FDA Approval for Gastric Cancer 
Pharmaceutical Technology Magazine
Merck & Co. has received approval from FDA for a gastric cancer indication for its anti-cancer biologic, Keytruda (pembrolizumab), the company said on Sep. 22, 2017. Keytruda is a blockbuster drug for Merck with 2016 sales of $1.4 billion. FDA approved ...
FDA Grants Accelerated Approval to Keytruda for Gastric Cancer Immuno-Oncology News

all 6 news articles » 


Dr. Yoon on Immunotherapy in Gastric Cancer - OncLive



OncLive
 
Dr. Yoon on Immunotherapy in Gastric Cancer 
OncLive
The FDA recently approved pembrolizumab for the treatment of patients with PD-L1?positive recurrent or advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received 2 or more lines of chemotherapy, including fluoropyrimidine- ...

 


Nivolumab represents 'new treatment option' for advanced gastric cancer - medwireNews



Nivolumab represents 'new treatment option' for advanced gastric cancer 
medwireNews
medwireNews: Nivolumab significantly prolongs survival, versus placebo, in heavily pretreated patients with unresectable gastric or gastro-esophageal junction cancer, ATTRACTION-2 study findings indicate. Narikazu Boku (National Cancer Center Hospital, ...